| Company/Division name | Insulet Corp. |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2017 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | China |
| City reshored to: | Acton |
| State(s) reshored to: | MA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | drug-delivery and insulin-management devices |
| What non-domestic negative factors made offshoring less attractive? | Quality/rework/warranty, Rising wages |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Customer responsiveness improvement, Lead time/Time to market, Proximity to customers/market |
